Judith Li
Partner @ Lilly Asia Ventures
Hong Kong, Hong Kong
Judith Li is a Series A investor at Lilly Asia Ventures in Hong Kong focused on Biotechnology and Health Care. Judith J. Li is a Partner at Lilly Asia Ventures (LAV), based in Hong Kong / Shanghai and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. Judith holds board appointments at a variety of LAV’s portfolio companies, including Crown Biosciences (6554:TT),Just Biotherapeutics, Veritas Genetics, and Nextcure. Her prior experience includes McKinsey’s New York office, hospital administration at Partners Healthcare, and co-founding an interventional nephrology medical device venture. Judith holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School, and currently resides in Hong Kong, splitting her time between Hong Kong, Shanghai, and the Bay Area.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Judith Li invests in
Stages Judith Li invests in
Countries Judith Li invests in
Investment Focus
Industry
- Biotechnology 5 (45%)
- Health Care 4 (36%)
- Therapeutics 3 (27%)
- Biopharma 2 (18%)
- Medical 1 (9%)
Stage
- Series A 4 (36%)
- Seed 2 (18%)
- Series B 2 (18%)
- Funding Round 2 (18%)
Country
- United States 4 (36%)
- China 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M / Series B / Jan 12, 2026 | |
|
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | Oct 05, 2023 | |
|
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $57M / Series A / Oct 05, 2023 | |
Rgenta Therapeutics
|
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its leadprograms and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.It was founded in 2018 and is headquartered in Cambridge, Massachusetts. | $52M / Series A / Nov 29, 2022 | |
|
Rgenta Therapeutics
|
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its leadprograms and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.It was founded in 2018 and is headquartered in Cambridge, Massachusetts. | $18M / Seed / May 25, 2021 | |
SciNeuro
|
SciNeuro is a biotechnology company focused on developing innovative medicines for patients with central nervous system diseases. | $100M / Series A / Dec 08, 2020 | |
Tmunity Therapeutics
|
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $35M / Series A / Apr 19, 2018 | |
|
Tmunity Therapeutics
|
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $100M / Series A / Jan 23, 2018 | |
Gritstone bio
|
Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. GritstoneOncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS. | $93M / Series B / Sep 07, 2017 | |
|
Tmunity Therapeutics
|
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation anddirection in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease. The founding team includes experts in T-cell biology, manufacturing, regulatory affairs, and clinical development, who collectively have an unparalleled track record of executing safe and effective cell and gene therapy clinical trials. In addition, Tmunity’s manufacturing platform has a proven track record of success in supporting multi-center clinical studies across diverse therapeutic indications. | $10M / Jan 12, 2016 | |
| See all 11 investments → | |||
Co-Investors
About Lilly Asia Ventures
Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities inChina, although they will consider investment opportunities elsewhere in east and south Asia.
Lilly Asia Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jiaxin Li
partner
|
|||
|
Judith Li
Partner
|
|||
Stella Shi
Venture Partner
|
|||
Yi Shi
Managing Director & Founder
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Judith Li invest in?
Judith Li invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Judith Li last invest?
The most recent investment recorded for Judith Li closed in Jan 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
